Combined treatment with ultrasound-targeted microbubble destruction technique and NM-aFGF-loaded PEG-nanoliposomes protects against diabetic cardiomyopathy-induced oxidative stress by activating the AKT/GSK-3β1/Nrf-2 pathway

Zhang, Ming; Zhu, Ningwei; Ma, Weiyin; Chen, Mengjia; Zheng, Lei

doi:10.1080/10717544.2020.1785052

Cited by 17 publications

(11 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, liposomes loaded with a non-mitogenic acid fibroblast growth factor and associated to a microbubble are designed to be precisely destroyed with the targeted ultrasound. This approach led to an improved systolic function and milder structural remodeling in STZ-treated rats ( 135 ). Effective cardiac gene delivery using the natural tropism of adeno-associated virus serotypes 9 and 6 toward the DCM myocardium are described ( 89 , 136 , 137 ).…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Muñoz-Cordova

Hernández‐Fuentes

López-Crisosto

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is a severe complication of diabetes developed mainly in poorly controlled patients. In DCM, several clinical manifestations as well as cellular and molecular mechanisms contribute to its phenotype. The production of reactive oxygen species (ROS), chronic low-grade inflammation, mitochondrial dysfunction, autophagic flux inhibition, altered metabolism, dysfunctional insulin signaling, cardiomyocyte hypertrophy, cardiac fibrosis, and increased myocardial cell death are described as the cardinal features involved in the genesis and development of DCM. However, many of these features can be associated with broader cellular processes such as inflammatory signaling, mitochondrial alterations, and autophagic flux inhibition. In this review, these mechanisms are critically discussed, highlighting the latest evidence and their contribution to the pathogenesis of DCM and their potential as pharmacological targets.

show abstract

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Muñoz-Cordova

Hernández‐Fuentes

López-Crisosto

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Cardiomyopathy, which is characterized by the presence of a dysfunctional heart muscle preventing the heart from properly pumping blood to other parts of the body, is described as occurring in patients suffering from diabetes or treated with certain drugs such as doxorubicin, [11,26,29,36,37,46,111]. Combining nanometric contrast agents (MBs) with a targeting ligand (FGP1) makes it possible to bring FGP1 specifically in the DHR, where FGP1 can promote endothelial vascular tissue/smooth muscle cell proliferation.…”

Section: The Various Heart Diseases That Can Be Detected/treated By U...mentioning

confidence: 99%

Nanomaterials as Ultrasound Theragnostic Tools for Heart Disease Treatment/Diagnosis

Alphandéry

2022

IJMS

View full text Add to dashboard Cite

A variety of different nanomaterials (NMs) such as microbubbles (MBs), nanobubbles (NBs), nanodroplets (NDs), and silica hollow meso-structures have been tested as ultrasound contrast agents for the detection of heart diseases. The inner part of these NMs is made gaseous to yield an ultrasound contrast, which arises from the difference in acoustic impedance between the interior and exterior of such a structure. Furthermore, to specifically achieve a contrast in the diseased heart region (DHR), NMs can be designed to target this region in essentially three different ways (i.e., passively when NMs are small enough to diffuse through the holes of the vessels supplying the DHR, actively by being associated with a ligand that recognizes a receptor of the DHR, or magnetically by applying a magnetic field orientated in the direction of the DHR on a NM responding to such stimulus). The localization and resolution of ultrasound imaging can be further improved by applying ultrasounds in the DHR, by increasing the ultrasound frequency, or by using harmonic, sub-harmonic, or super-resolution imaging. Local imaging can be achieved with other non-gaseous NMs of metallic composition (i.e., essentially made of Au) by using photoacoustic imaging, thus widening the range of NMs usable for cardiac applications. These contrast agents may also have a therapeutic efficacy by carrying/activating/releasing a heart disease drug, by triggering ultrasound targeted microbubble destruction or enhanced cavitation in the DHR, for example, resulting in thrombolysis or helping to prevent heart transplant rejection.

show abstract

“…(DSPE-PEG2000) were dissolved in a mixture of chloroform and methanol in a molar ratio of 4:5:1, and then was operated by a JY 92-II ultrasonic equipment at 30°C for 3 min (frequency and power parameters:40 kHz, 160 W). After the cationic lipid microbubbles solution was frozen at −20°C in the refrigerator and was lyophilized in vacuum freeze dryer at pressure of 15 Pa (at −48°C for 15 h, and then up to 10°C for no more than 5 h), the cationic lipid microbubbles (150 mg) were added to the mixture of 0.9% normal saline and glycerol (volume ratio 4:1.5 ml) for dispersion (Zhang et al, 2020). The liquid was transferred to a borosilicate glass bottle and filled with inert gas SF6.…”

Section: Fabrication Of Cationic Lipid Microbubblesmentioning

confidence: 99%

aFGF Targeted Mediated by Novel Nanoparticles-Microbubble Complex Combined With Ultrasound-Targeted Microbubble Destruction attenuates Doxorubicin-Induced Heart Failure via Anti-Apoptosis and Promoting Cardiac Angiogenesis

et al. 2021

View full text Add to dashboard Cite

The purpose of this study was to evaluate the protective effect of acidic fibroblast growth factor targeted mediated by novel nanoparticles–cationic lipid microbubbles complex (aFGF–NP + CPMBs) combined with ultrasound targeted microbubble destruction (UTMD)on doxorubicin–induced heart failure (HF)and its mechanism. Heart failure rats induced by intraperitoneal injection with doxorubicin (DOX) to achieve cummulative dose of 15mg/kg for continuous 6 weeks showed left ventricular dysfunction, seriously oxidative stress, cardiomyocyte apoptosis, and decrease of myocardial vascular density. In contrast, aFGF–NP + CPMBs combined with UTMD therapy (3ug/kg, caudal vein injection, twice a week, 6weeks)prominently ameliorated left ventricular dysfunction by increased ejection fraction (EF) and fractional shortening (FS), decreased brain natriuretic peptide (BNP); strengthened the ability of antioxidant stress confirmed by increasing the activity of SOD and reducing the production of MDA; exerted the effect of anti–cardiomyocyte apoptosis and promotion angiogenesis by inhibited Bax expression and increased Bcl–2 expression and platelet endothelial cell adhesion molecule (CD31) expression. Taken together, the research suggested that aFGF targeted mediated by novel nanoparticles–cationic lipid microbubbles complex combined with UTMD should be a promising targeted treatment for heart failure.

show abstract

Combined treatment with ultrasound-targeted microbubble destruction technique and NM-aFGF-loaded PEG-nanoliposomes protects against diabetic cardiomyopathy-induced oxidative stress by activating the AKT/GSK-3β1/Nrf-2 pathway

Cited by 17 publications

References 55 publications

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Nanomaterials as Ultrasound Theragnostic Tools for Heart Disease Treatment/Diagnosis

aFGF Targeted Mediated by Novel Nanoparticles-Microbubble Complex Combined With Ultrasound-Targeted Microbubble Destruction attenuates Doxorubicin-Induced Heart Failure via Anti-Apoptosis and Promoting Cardiac Angiogenesis

Contact Info

Product

Resources

About